Navigation Links
Peakdale Molecular Announces GBP 1 Million Funding to Support Expansion and Growth

CHAPEL EN LE FRITH, England, January 9 /PRNewswire/ -- Peakdale Molecular Ltd a leading provider in specialist chemistry services to the pharmaceutical industry has announced today that they have successfully completed a GBP1m round of equity funding which will enable Peakdale to continue the expansion of its facilities in the UK to support its continued rapid growth.

The investors in this round were led by Solon Ventures LP, advised by Solon Ventures Ltd, and were supported by a number of existing investors.

Commenting on the deal, Peakdale's Commercial Director Ray Fisher said: "I am very grateful for being introduced to the team at Solon Ventures at such an important time in Peakdale's history. With our plans for aggressive growth, Solon's sector knowledge and desire to actively support such activities, together we appear to have the ingredients of a perfect synergy."

Adding to this, Solon Ventures Ltd Managing Director Angus Whiteley said: "We are delighted to be involved with Ray and his team at Peakdale in this exciting stage of its development. With its excellent reputation and high quality services, we believe Peakdale is very well placed to continue to support the pharmaceutical and biotech industries in the future. We look forward to playing an active role, based on our experience of the sector, in helping the company achieve its growth and international aspirations."

About Peakdale Molecular

Peakdale Molecular was founded in 1992. Today the Company's customers include the majority of the major global pharmaceutical companies and an increasing number of biotechnology companies. Its teams of chemists combine experience in pharmaceutical R&D and process development, medicinal chemistry, parallel synthesis and fine chemicals to deliver unique chemistry solutions to a range of drug discovery challenges.

The application of less commonly used chemistry, including high temperature/pressure reactions, proprietary heterocyclic chemistry and nucleoside synthesis, enables Peakdale's chemists to generate unique compounds for drug discovery. Peakdale operates in several distinct markets providing novel screening compounds, targeted screening libraries, catalogue intermediates, custom synthesis and contract research. Further information about the Company can be obtained at

About Solon Ventures LP

Solon Ventures LP is a Jersey-based limited partnership that invests in private UK healthcare and technology companies. The fund is advised by Solon Ventures Ltd, a UK company that advises GBP35m of venture capital investment for a range of clients.

Peakdale Molecular

Ray Fisher

Commercial Director

Peakdale Molecular Ltd

Peakdale Science Park

Sheffield Road


High Peak

SK23 0PG


Tel +44(0)1298-816700

Fax +44(0)1298-816701

Angus Whiteley

Managing Director

Solon Ventures Ltd

24 Old Bond Street




Tel +44(0)20-7535-4912

Fax +44(0)20-7493-9172

SOURCE Peakdale Molecular
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Center for Molecular Medicine Only Regional Provider of Test Suggested in FDA Alert on Prescribing Codeine to Nursing Mothers
2. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
3. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
4. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
5. Glycominds Joins Biomolecular Photonic (BMP) Consortium to Develop New Molecular Imaging Technique
6. Former Pfizer Director of Inflammation Molecular Sciences to Spearhead Velcura Therapeutics Inflammatory Disease Initiatives
7. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
8. Astex Drug Candidates to be Featured at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
9. Center for Molecular Medicine One of the First Midwest Labs to Offer Advanced Test for Patients with Metastatic Breast Cancer
10. Delivering Molecular Imaging Solutions Across Clinical Specialties: Siemens Showcases New Technologies at RSNA 2007
11. Center for Molecular Medicine Offers Xceed Ziplex(TM) Services to Research Community
Post Your Comments:
(Date:11/25/2015)... HOLLISTON, Mass. , Nov. 25, 2015 ... a biotechnology company developing bioengineered organ implants for life-threatening ... will present at the LD Micro "Main Event" investor ... PT. The presentation will be webcast live and posted ... also be available at the conference for one-on-one meetings ...
(Date:11/25/2015)... ... 25, 2015 , ... A long-standing partnership between the Academy ... been formalized with the signing of a Memorandum of Understanding. , AMA Executive ... Karl Minter and Capt. Albert Glenn Tuesday, November 24, 2015, at AMA Headquarters ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and Zachary Apte, ... their initial angel funding process. Now, they are paying it forward to other ... stage investments in the microbiome space. In this, they join other successful ...
(Date:11/24/2015)... Nov. 24, 2015 Cepheid (NASDAQ: CPHD ... at the following conference, and invited investors to participate ...      Tuesday, December 1, 2015 at 11.00 a.m. ...      Tuesday, December 1, 2015 at 11.00 a.m. ... New York, NY      Tuesday, December ...
Breaking Biology Technology:
(Date:11/12/2015)... , Nov. 12, 2015  A golden retriever ... Duchenne muscular dystrophy (DMD) has provided a new lead ... Children,s Hospital, the Broad Institute of MIT and Harvard ... Brazil . Cell, pinpoints ... dogs "escape" the disease,s effects. The Boston Children,s lab ...
(Date:11/12/2015)... LONDON , Nov. 11, 2015   ... and reliable analytical tools has been paving the ... and qualitative determination of discrete analytes in clinical, ... sensors are being predominantly used in medical applications, ... and environmental sectors due to continuous emphasis on ...
(Date:11/10/2015)... LONDON , Nov. 10, 2015 /PRNewswire/ ... segmented on the basis of product, type, ... segments included in this report are consumables, ... this report are safety biomarkers, efficacy biomarkers, ... in this report are diagnostics development, drug ...
Breaking Biology News(10 mins):